Madison, NJ - The Medical Innovation Impact Index (MI3), a new method for evaluating the impact of regulation on medical innovation, has been developed at the Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s (FDU) Rothman Institute of Innovation and Entrepreneurship. The inaugural MI3 Alert pertains to new FDA (Food & Drug Administration) draft guidance documents and a Senate proposal for accelerating the approval of certain medical devices.
0 Comments
Princeton, NJ - According to Rose Huber, "The measles virus can cause serious disease in children by temporarily suppressing their immune systems. This vulnerability was previously thought to last a month or two, however, a new study shows that children may in fact live in the immunological shadow of measles for up to three years, leaving them highly susceptible to a host of other deadly diseases."
Princeton, NJ - According to Brenda Mikeo of Princeton Research, "José Avalos is an assistant professor of chemical and biological engineering, jointly appointed with the Andlinger Center for Energy and the Environment. His interests lie in the use of biotechnology to address important issues in sustainable energy, the environment, industry, and human health. Avalos’ research focuses specifically on synthetic biology and metabolic engineering for the production of biofuels and bio-derived chemicals."
Sewell, NJ - In 1981, George and Lucy Malmberg decided they wanted to become entrepreneurs, so they purchased a bankrupt pharmacy in Sewell. Breaking even was not an easy task for the couple, but they were dedicated to making the business work by opening early and closing late.
Trenton, NJ - Angel Medical Systems in Shrewsbury realizes that many people do not recognize the symptoms of heart attacks or do not take the warning signs seriously enough. The growing technology company also knows that every minute counts when dealing with a heart attack. With these factors in mind, Angel Medical Systems developed an implantable device that monitors an individual’s heart, alerting to changes often seen before, or at the onset of, a heart attack.
Trenton, NJ - From June 15 to June 18, New Jersey’s life sciences prowess will be on display at the Bio International Convention in Philadelphia, the international industry event that will feature more and more than 300 academic institutions, including major research labs, and government agencies. Including ancillary professionals such as lawyers, accountants and venture capitalists, the three-day event is expected to attract more than 16,000 attendees.
Washington D.C. - According to John Castellani, "The U.S. patent system is the critical legal shield protecting medical innovations as they make their way from America’s labs to the patients in every state who need, want and deserve them."
Woodcliff, NJ - Endo International plc and Woodcliff Lakes-based Par Pharmaceutical Holdings, Inc. today announced that they have entered into a definitive agreement under which Endo will acquire privately-held Par from TPG in a transaction valued at $8.05 billion, including assumption of Par debt. The combination will create a leading specialty pharmaceutical company with a generics business that is one of the industry’s fastest growing and among the top five as measured by U.S. sales. It is also expected to help drive long-term double-digit revenue growth for Endo.
Cranbury, NJ - VaxInnate Corporation, a biotech firm, announced recently that it has named a new chief scientific officer, among several appointments, as it aims to drive pipeline growth, according to Eric Strauss of NJBIz.
Trenton, NJ - According to Bloomber News, "L'Oreal needs human skin. Lots of it. That's why the French cosmetics giant earlier this month announced that it's partnering with bioprinting startup Organovo to figure out how to 3D print living, breathing derma that can be used to test products for toxicity and efficacy. "We're the first beauty company Organovo has worked with," says Guive Balooch, global vice president of L'Oreal's tech incubator."
Washington D.C. - According Andrew Kitchenman of NJ Spotlight, "The 21st Century Cures Act attracts bipartisan NJ sponsors Pallone and Lance, draws praise from researchers and industry. One of the goals of the bill is to foster “personalized medicine,” in which treatments are tailored to meet the individual genetic profile of a patient." "The importance of these industries to the state helps explain why two of the bipartisan bill’s leading House advocates are from New Jersey: U.S. Rep. Frank Pallone Jr. (D-6th), one of its four cosponsors, and U.S. Rep. Leonard Lance (R-7th)."
Union, NJ - The Institute for Life Science Entrepreneurship (ILSE), a non-profit translational science research integrator, accelerator and incubator, and ATCC, the premier global biological materials resource and standards organization, announced today a collaboration to establish The ATCC Center for Translational Microbiology at ILSE (the “Center”). The focus of the Center will be on key challenges identified by both ATCC and ILSE in current translational microbiology, including antimicrobial resistance, synthetic biology, microbial bioinformatics and the microbiome.
South Plainfield, NJ - PTC Therapeutics, Inc. announced it has launched STRIVE (Strategies to Realize Innovation, Vision and Empowerment), an awards program aimed at providing funds to patient advocacy organizations to develop unique and collaborative programs that will make meaningful contributions to the rare disease community by increasing awareness, diagnosis, education or fostering development of future patient advocates. The program, in its inaugural year, will focus on Duchenne muscular dystrophy (DMD).
Trenton, NJ – Proposed legislation that will allow greater patient access to more affordable FDA-approved biologic medicines was passed unanimously by the New Jersey Assembly Health and Human Services Committee today. The bill, A2477, also includes provisions for physician notification when a biosimilar bill is substituted for a biologic drug.
Trenton, NJ - Cigna and Regional Cancer Care Associates LLC (RCCA) have started a program that aims to improve care for people receiving chemotherapy to treat any type of cancer. The program is an extension of Cigna Collaborative Care, a value-based initiative that uses incentives to engage health care professionals and help drive improved health, affordability and patient experience. Cigna Collaborative Care initially focused on large primary care physician groups but was expanded to include hospitals, small primary care practices and specialists, including oncologists.
|
Do not miss a single innovative moment and sign up for our newsletter!
|